Shattuck Labs Q4 2025 Earnings Report

Shattuck Labs EPS Results

• Actual EPS: -$0.12
• Consensus EPS: -$0.12
• Beat/Miss: Met Expectations
• One Year Ago EPS: N/A

Shattuck Labs Revenue Results

• Actual Revenue: ($1.00) million
• Expected Revenue: $0.17 million
• Beat/Miss: Missed by -$1.17 million
• YoY Revenue Growth: N/A

Shattuck Labs Announcement Details

• Quarter: Q4 2025
• Date: 3/5/2026
• Time: Before Market Opens
• Conference Call Date: Thursday, March 5, 2026
• Conference Call Time: 6:30AM ET

Shattuck Labs (NASDAQ:STTK) (NASDAQ: STTK) is a clinical‐stage biotechnology company headquartered in Cambridge, Massachusetts. The company is focused on developing immunotherapeutic vaccines to prevent and treat substance use disorders, with an initial emphasis on opioids. Shattuck Labs employs a proprietary hapten‐carrier conjugate technology designed to generate high‐affinity drug‐specific antibodies that sequester target molecules in the bloodstream and reduce their passage across the blood‐brain barrier.

The company’s lead program targets fentanyl, a synthetic opioid responsible for a significant proportion of overdose fatalities. Preclinical studies have demonstrated that vaccinated animals produce robust anti‐fentanyl antibody titers and are protected against lethal and sublethal fentanyl challenges. Shattuck Labs is advancing its vaccine candidate through IND‐enabling studies and plans to initiate first‐in‐human trials to evaluate safety, immunogenicity, and its potential to block the psychoactive effects of fentanyl.

Founded in 2017, Shattuck Labs was established to address the growing public health crisis posed by opioid misuse and overdose. The company leverages insights from immunology and vaccinology, collaborating with academic partners and contract manufacturing organizations to streamline development and scale up production. Shattuck Labs serves the U.S. market and is preparing for broader geographic reach as its clinical programs progress.

Shattuck Labs is led by Chief Executive Officer Craig H. Wheeler, who brings extensive experience in biopharmaceutical R&D and commercial strategy. The management team includes experts in vaccine formulation, regulatory affairs, and translational medicine. Through its focused pipeline and innovative platform, Shattuck Labs aims to pioneer a new class of non‐addictive, immunotherapeutic treatments for substance use disorders.